Blocking a specific protein to prevent lung scarring
Inhibition of Fgr Prevents Pulmonary Fibrosis
This study is looking at how a new drug that targets a protein called Fgr might help prevent lung scarring in people with pulmonary fibrosis, aiming to protect healthy cells while reducing damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10901018 on NIH RePORTER |
What this research studies
This research investigates how targeting a specific protein called Fgr can help prevent pulmonary fibrosis, a condition that causes scarring in the lungs. The approach involves using a drug that inhibits Fgr, which has been shown to play a role in the development of fibrosis in senescent cells. By focusing on this specific target, the research aims to reduce harmful effects while preserving beneficial cells. The study will utilize advanced techniques like RNA sequencing to understand the mechanisms involved in fibrosis better.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with pulmonary fibrosis, particularly those with idiopathic pulmonary fibrosis or fibrosis resulting from COVID-19.
Not a fit: Patients with other forms of lung disease unrelated to fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively prevent or reduce lung scarring in patients.
How similar studies have performed: Previous research has shown promise in targeting specific proteins to mitigate fibrosis, suggesting that this approach could be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Mukherjee, Amitava — University of Pittsburgh at Pittsburgh
- Study coordinator: Mukherjee, Amitava
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.